Search Results Label

Reproductive and developmental toxicology data from trivalent influenza vaccines do not predict an increased risk of developmental abnormalities.

https://www.seqirus.ca/-/media/seqirus-canada/docs-en/flucelvax-quad-ca-pm-2-approved-8mar2021.pdf

Seqirus Announces Health Canada Approval of Expanded Age Indication

https://www.seqirus.ca/news/seqirus-announces-health-canada-approval-of-expanded-age-indication

Seqirus Ready to Reinforce Canada’s Influenza Pandemic Preparedness Plans

https://www.seqirus.ca/news/seqirus-ready-to-reinforce-canadas--influenza-pandemic-preparedness-plans

9.2 Drug Interactions Overview No interaction studies have been performed on interaction between influenza vaccines in general and other vaccines or medications.

https://www.seqirus.ca/-/media/seqirus-canada/docs-en/afluria-tetra-product-monograph--februray-19th-2021.pdf

Seqirus Presents Key Insights on Influenza Vaccines at the Canadian Immunization Conference 2020

https://www.seqirus.ca/news/seqirus-presents-key-insights-on-influenza-vaccines

Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.

https://www.seqirus.ca/our-company

Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.

https://www.seqirus.ca/

Vaccination with AGRIFLU® (influenza vaccine, surface antigen, inactivated) cannot cause influenza because the vaccine does not contain live virus.

https://www.seqirus.ca/-/media/seqirus-canada/docs-en/2020-agriflu-product-monograph--revised-23oct2020.pdf

Reproductive and developmental toxicology data from trivalent influenza vaccines do not predict an increased risk of developmental abnormalities.

https://www.seqirus.ca/-/media/seqirus-canada/docs-en/2020-flucelvax-productmonograph.pdf

Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines.

https://www.seqirus.ca/-/media/seqirus-canada/docs-fr/2020-agriflu-monographie-de-produit-revised-26oct2020.pdf